These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 29148319)

  • 21. Drug benefit changes under Medicare Advantage Part D: heterogeneous effects on pharmaceutical use and expenditures.
    Ettner SL; Steers WN; Turk N; Quiter ES; Mangione CM
    J Gen Intern Med; 2011 Oct; 26(10):1195-200. PubMed ID: 21710313
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Medicare's Variation in Out-of-Pocket Costs for Prescriptions: The Irrational Examples of In-Hospital Observation and Home Infusion.
    Wright B; Dusetzina SB; Upchurch G
    J Am Geriatr Soc; 2018 Dec; 66(12):2249-2253. PubMed ID: 30264858
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Medicare part D and changes in prescription drug use and cost burden: national estimates for the Medicare population, 2000 to 2007.
    Briesacher BA; Zhao Y; Madden JM; Zhang F; Adams AS; Tjia J; Ross-Degnan D; Gurwitz JH; Soumerai SB
    Med Care; 2011 Sep; 49(9):834-41. PubMed ID: 21544002
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Per-Prescription Drug Expenditure by Source of Payment and Income Level in the United States, 1997 to 2015.
    Tang W; Xie J; Kong F; Malone DC
    Value Health; 2019 Aug; 22(8):871-877. PubMed ID: 31426927
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessing the impact of coverage gaps in the Medicare Part D drug benefit.
    Hudson N
    Find Brief; 2008 Apr; 11(3):1-3. PubMed ID: 18441611
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost minimization of medicare part D prescription drug plan expenditures.
    Patel RA; Lipton HL; Cutler TW; Smith AR; Tsunoda SM; Stebbins MR
    Am J Manag Care; 2009 Aug; 15(8):545-53. PubMed ID: 19670958
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Providing prescription drug coverage to the elderly: America's experiment with Medicare Part D.
    Duggan M; Healy P; Morton FS
    J Econ Perspect; 2008; 22(4):69-92. PubMed ID: 19768843
    [No Abstract]   [Full Text] [Related]  

  • 28. The impact of Medicare part D on income-related inequality in pharmaceutical expenditure.
    Carvalho N; Petrie D; Chen L; Salomon JA; Clarke P
    Int J Equity Health; 2019 Apr; 18(1):57. PubMed ID: 30992000
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Benzodiazepine use and expenditures for Medicare beneficiaries and the implications of Medicare Part D exclusions.
    Yang HW; Simoni-Wastila L; Zuckerman IH; Stuart B
    Psychiatr Serv; 2008 Apr; 59(4):384-91. PubMed ID: 18378837
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Medicare part D after 2 years.
    Joyce GF; Goldman DP; Vogt WB; Sun E; Jena AB
    Am J Manag Care; 2009 Aug; 15(8):536-44. PubMed ID: 19670957
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Medicare Part D roulette: potential implications of random assignment and plan restrictions.
    Patel RA; Walberg MP; Woelfel JA; Amaral MM; Varu P
    Medicare Medicaid Res Rev; 2013; 3(2):. PubMed ID: 24753963
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prescription drug coverage among elderly and disabled Americans: can Medicare-Part D reduce inequities in access?
    Kanavos P; Gemmill-Toyama M
    Int J Health Care Finance Econ; 2010 Sep; 10(3):203-18. PubMed ID: 20213234
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of drug coverage on medical expenditures among the elderly.
    Gilman BH; Gage B; Haber S; Hoover S; Aggarwal J
    Health Care Financ Rev; 2007; 29(1):103-18. PubMed ID: 18624083
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Changes in drug utilization during a gap in insurance coverage: an examination of the medicare Part D coverage gap.
    Polinski JM; Shrank WH; Huskamp HA; Glynn RJ; Liberman JN; Schneeweiss S
    PLoS Med; 2011 Aug; 8(8):e1001075. PubMed ID: 21857811
    [TBL] [Abstract][Full Text] [Related]  

  • 35. How Did Medicare Part D Affect Racial and Ethnic Disparities in Drug Coverage?
    Mahmoudi E; Levy HG
    J Gerontol B Psychol Sci Soc Sci; 2016 May; 71(3):581-9. PubMed ID: 25533317
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of Medicare Part D for Medicare-age adults with arthritis: prescription use, prescription expenditures, and medical spending from 2005 to 2008.
    Cheng LI; Rascati KL
    Arthritis Care Res (Hoboken); 2012 Sep; 64(9):1423-9. PubMed ID: 22508663
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Demand for prescription drugs under non-linear pricing in Medicare Part D.
    Jung K; Feldman R; McBean AM
    Int J Health Care Finance Econ; 2014 Mar; 14(1):19-40. PubMed ID: 24214101
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improvements in Medicare Part D risk adjustment: beneficiary access and payment accuracy.
    Kautter J; Ingber M; Pope GC; Freeman S
    Med Care; 2012 Dec; 50(12):1102-8. PubMed ID: 22922436
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Growing differences between Medicare beneficiaries with and without drug coverage.
    Poisal JA; Murray L
    Health Aff (Millwood); 2001; 20(2):74-85. PubMed ID: 11260961
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prescription drug coverage, utilization, and spending among Medicare beneficiaries.
    Davis M; Poisal J; Chulis G; Zarabozo C; Cooper B
    Health Aff (Millwood); 1999; 18(1):231-43. PubMed ID: 9926660
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.